A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
for HER2-positive Gastric Cancer
Drug: Rilvegostomig
Sites in Charleston +45 more locations
Sponsor: AstraZeneca
Sex: All·Age: 18+
Code: NCT06764875·Phase 3·Recruiting·Listed Jan 2025